Table of Contents
Hepatitis Research and Treatment
Volume 2014 (2014), Article ID 615621, 5 pages
http://dx.doi.org/10.1155/2014/615621
Clinical Study

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B

Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar

Received 16 June 2014; Revised 10 August 2014; Accepted 28 August 2014; Published 30 September 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Hamid Ullah Wani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Leung, “Treatment of chronic hepatitis B: case selection and duration of therapy,” Journal of Gastroenterology and Hepatology, vol. 17, no. 4, pp. 409–414, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. T.-T. Chang, C.-L. Lai, R.-N. Chien et al., “Four years of lamivudine treatment in Chinese patients with chronic hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 19, no. 11, pp. 1276–1282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Pramoolsinsup, “Management of viral hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 17, no. 1, pp. S125–S145, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Martín-Carbonero and E. Poveda, “Hepatitis B virus and HIV infection,” Seminars in Liver Disease, vol. 32, no. 2, pp. 114–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Wang, R. Fan, J. Sun, and J. Hou, “Prevention and management of drug resistant hepatitis B virus infections,” Journal of Gastroenterology and Hepatology, vol. 27, no. 9, pp. 1432–1440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Manolakopoulos, S. Bethanis, J. Elefsiniotis et al., “Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 6, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Tanaka, A. E. T. Yeo, E. Orito et al., “Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection,” Journal of Gastroenterology, vol. 39, no. 8, pp. 769–775, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M.-J. Sheu, H.-T. Kuo, C.-Y. Lin et al., “Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 4, pp. 447–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Tsubota, Y. Arase, Y. Suzuki et al., “Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 20, no. 3, pp. 426–432, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. L. J. Sun, J. W. Yu, Y. H. Zhao, P. Kang, and S. C. Li, “Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure,” Journal of Gastroenterology and Hepatology, vol. 25, no. 3, pp. 583–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Buti, F. Sánchez, M. Cotrina et al., “Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B,” Journal of Infectious Diseases, vol. 183, no. 8, pp. 1277–1280, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Ide, R. Kumashiro, Y. Koga et al., “A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine,” The American Journal of Gastroenterology, vol. 98, no. 9, pp. 2048–2051, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Kim, S. K. Yu, Y. S. Seo et al., “Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy,” Journal of Gastroenterology and Hepatology, vol. 22, no. 8, pp. 1220–1225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Fung, F. Wong, M. Hussain, and A. S. F. Lok, “Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B,” Journal of Viral Hepatitis, vol. 11, no. 5, pp. 432–438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Marrone, R. Zampino, P. Karayannis et al., “Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 8, pp. 707–714, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Honkoop, H. G. M. Niesters, R. A. M. de Man, A. D. M. E. Osterhaus, and S. W. Schalm, “Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns,” Journal of Hepatology, vol. 26, no. 6, pp. 1393–1395, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Torre, E. G. Giannini, M. Basso, V. Fazio, V. Savarino, and A. Picciotto, “Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients,” Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 1, pp. 47–50, 2011. View at Google Scholar · View at Scopus
  18. M. Ha, G. Zhang, S. Diao et al., “Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy,” Internal Medicine, vol. 51, no. 12, pp. 1509–1515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. H. L. Y. Chan, Y. C. Chen, E. J. Gane et al., “Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis,” Journal of Viral Hepatitis, vol. 19, no. 10, pp. 732–743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Jiang, J. Wang, and W. Zhao, “Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 32, no. 1, pp. 11–18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. G. Peters, H. W. Hann, P. Martin et al., “Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B,” Gastroenterology, vol. 126, no. 1, pp. 91–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Kim, J. H. Park, D. I. Park et al., “Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy,” Journal of Gastroenterology and Hepatology, vol. 25, no. 8, pp. 1374–1380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Sherman, C. Yurdaydin, H. Simsek et al., “Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologie, biochemical, and serology outcomes through 96 weeks,” Hepatology, vol. 48, no. 1, pp. 99–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Kanwal, I. M. Gralnek, P. Martin, G. S. Dulai, M. Farid, and B. M. R. Spiegel, “Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis,” Annals of Internal Medicine, vol. 142, no. 10, pp. 821–831, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Solari, G. Hijar, R. Zavala, and J. M. Ureta, “Economic evaluation of antiviral treatment for chronic hepatitis B: a systematic review,” Revista Peruana de Medicina Experimental y Salud Publica, vol. 27, no. 1, pp. 68–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Sun, W.-X. Qin, Y.-P. Li, and X.-H. Jiang, “Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence,” Journal of Gastroenterology and Hepatology, vol. 22, no. 9, pp. 1369–1377, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Y. Peng, R. N. Chien, and Y. F. Liaw, “Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy,” Journal of Hepatology, vol. 57, no. 2, pp. 442–450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. K. Fung and A. S. F. Lok, “Management of patients with hepatitis B virus-induced cirrhosis,” Journal of Hepatology, vol. 42, no. 1, pp. S54–S64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States,” Clinical Gastroenterology and Hepatology, vol. 2, no. 2, pp. 87–106, 2004. View at Publisher · View at Google Scholar · View at Scopus